GNCA
$2.06
Genocea Biosciences
($.04)
(1.90%)
GNCA
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($0.21)
Revenue:  $0.00 Mil
Thursday
Jan 28
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Thursday, October 29, 2020

What do you expect when GNCA reports earnings?
Beat
Meet
Miss

Where is GNCA's stock price going from here?
Up
Flat
Down
Stock chart of GNCA
Analysts
Summary of analysts' recommendations for GNCA
Score
Grade
Pivots
Resistance
$2.24
$2.19
$2.14

$2.09

Support
$2.05
$2.00
$1.96
Tweet
Growth
Description
Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbZoetisMerck & Co.PfizerJohnson & JohnsonEli Lilly